AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19014751 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (500‐2500 mg/day)
Number of subjects: 521
Study 19014751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 16292090 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii 500 mg twice daily
Number of subjects: 389
Study 16292090 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 389
Study 12785003 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (40 microg/kg/min)
Number of subjects: 21
Study 12785003 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 21
Study 10596504 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally based parenting skills classes
Number of subjects: 303
Study 10596504 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 303
Study 8692554 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus dexamethasone and diphenhydramine
Number of subjects: 0
Study 8692554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 0
Study 8692554 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide plus methylprednisolone
Number of subjects: 0
Study 8692554 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone plus diphenhydramine
Number of subjects: 0
Study 1667753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrophosphate dentifrice (F-Antibelag Gel + K4P2O7/Na4P2O7)
Number of subjects: 60
Study 1667753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (F-Antibelag Gel)
Number of subjects: 60
Study 7068078 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven ultra
Number of subjects: 60
Study 7068078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31262153 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (twice a week for 3 months)
Number of subjects: 55
Study 31262153 — intervention group
Group type: COMPARATOR
Intervention: Control group (prescribed treatment without strength training)
Number of subjects: 55
Study 28600624 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/2
Number of subjects: 78
Study 28600624 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/4
Number of subjects: 78
Study 28600624 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/6
Number of subjects: 78
Study 28600624 — intervention group
Group type: COMPARATOR
Intervention: O2/air groups
Number of subjects: 78
Study 28600624 — intervention group
Group type: EXPERIMENTAL
Intervention: AGC performance
Number of subjects: 78
Study 28600624 — intervention group
Group type: EXPERIMENTAL
Intervention: Wash-in speeds
Number of subjects: 78
Study 27624485 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient training programme including detailed information on their condition and practical training in using a portable blood coagulation monitor.
Number of subjects: 333
Study 27624485 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient training programme
Number of subjects: 333
Study 27624485 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 333
Study 24623024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT) with a target blood glucose range of 4.4‐6.1 mmol/L
Number of subjects: 447
Study 24623024 — intervention group
Group type: COMPARATOR
Intervention: Intermediate insulin therapy (IT) with a target blood glucose range of 7.7‐10.0 mmol/L
Number of subjects: 447
Study 24623024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT)
Number of subjects: 447
Study 22278087 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-CBT training (n = 90)
Number of subjects: 182
Study 22278087 — intervention group
Group type: COMPARATOR
Intervention: Training as Usual (TAU; n = 92)
Number of subjects: 182
Study 20227728 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene caps
Number of subjects: 96
Study 20227728 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene occlusive skin wrap
Number of subjects: 96
Study 20227728 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional drying)
Number of subjects: 96
Study 17941876 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide monotherapy (120 mg before meals)
Number of subjects: 135
Study 17941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg before meals) + Metformin (up to 1000 mg bid)
Number of subjects: 135
Study 17941876 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (up to 5 mg bid) + Metformin (up to 1000 mg bid)
Number of subjects: 135
Study 17941876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide + Metformin
Number of subjects: 135
Study 15699447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (3 months jogging)
Number of subjects: 31
Study 15699447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 31
Study 15699447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 31
Study 15699447 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 12802092 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tongue strength exercises using a tongue depressor
Number of subjects: 31
Study 12802092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises using the Iowa Oral Performance Instrument
Number of subjects: 31
Study 12802092 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 31
Study 11105936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0.9 mg/kg)
Number of subjects: 18
Study 9065557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu-related molecules of 35 to 41 kDa detected in the membrane of small-cell lung cancers and neuroblastomas using immunofluorescence, absorption assays, Western blotting on membrane fractions, and surface biotinylation.
Number of subjects: 0
Study 9065557 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Hu-related antigens in the nucleus and membrane of small-cell lung cancer and neuroblastomas.
Number of subjects: 0
Study 8452191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 289
Study 8452191 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 3,000 mg
Number of subjects: 289
Study 2878173 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin started within 3 days of heparin (group S)
Number of subjects: 266
Study 2878173 — intervention group
Group type: COMPARATOR
Intervention: Warfarin started after 7 days of heparin (group L)
Number of subjects: 266
Study 31706553 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia (DC)
Number of subjects: 851
Study 31706553 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia (BC)
Number of subjects: 851
Study 29878341 — intervention group
Group type: EXPERIMENTAL
Intervention: DFN-02 (sumatriptan 10 mg with DDM)
Number of subjects: 107
Study 28013104 — intervention group
Group type: EXPERIMENTAL
Intervention: UNDERPIN-ICU program
Number of subjects: 8
Study 26316137 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral image-guided gastrostomy (POG)
Number of subjects: 60
Study 26316137 — intervention group
Group type: COMPARATOR
Intervention: Radiologically created pigtail gastrostomy (PG)
Number of subjects: 60
Study 26316137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both POG and PG
Number of subjects: 60
Study 23320445 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative uses generation
Number of subjects: 0
Study 23320445 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA)
Number of subjects: 0
Study 21500166 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 40
Study 21500166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18373223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 97
Study 18373223 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 97
Study 16762887 — intervention group
Group type: EXPERIMENTAL
Intervention: Avastin plus irinotecan (group A)
Number of subjects: 90
Study 16762887 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (group B)
Number of subjects: 90
Study 16762887 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX7 (group C)
Number of subjects: 90
Study 12699521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.1 mg kg(‐1) i.m. premedication
Number of subjects: 50
Study 12699521 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 50
Study 11033836 — intervention group
Group type: COMPARATOR
Intervention: rhIL-11 (recombinant human interleukin-11)
Number of subjects: 0
Study 11033836 — intervention group
Group type: COMPARATOR
Intervention: rhIL-11
Number of subjects: 0
Study 11033836 — intervention group
Group type: COMPARATOR
Intervention: rhIL-11 in combination with G-CSF (filgrastim)
Number of subjects: 0
Study 9193196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose quetiapine fumarate (<= 750 mg/d)
Number of subjects: 286
Study 9193196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose quetiapine fumarate (<= 250 mg/d)
Number of subjects: 286
Study 9193196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 7712685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg daily)
Number of subjects: 18
Study 7712685 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg daily)
Number of subjects: 18
Study 7712685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29983230 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500mg/day)
Number of subjects: 60
Study 29983230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28030431 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696/amlodipine (200/5 mg/day)
Number of subjects: 266
Study 28030431 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg/day)
Number of subjects: 266
Study 28030431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 266
Study 26220283 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoRings colonoscopy
Number of subjects: 116
Study 26220283 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 116
Study 24949107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mothers advised on caries prevention)
Number of subjects: 649
Study 24949107 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (mothers not advised on caries prevention)
Number of subjects: 649
Study 24949107 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract, but implied as a separate group)
Number of subjects: 649
Study 23061793 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 591
Study 23061793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 20552173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 36
Study 20552173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17426316 — intervention group
Group type: COMPARATOR
Intervention: Standard In‐Person Behavioral Weight Control Program (SBWP)
Number of subjects: 57
Study 17426316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Technology-Based Program (INT-TECH)
Number of subjects: 57
Study 17426316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Technology-Based Program (CON-TECH)
Number of subjects: 57
Study 15803442 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic drug regimens
Number of subjects: 0
Study 15803442 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrinkage estimation
Number of subjects: 0
Study 15803442 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 0
Study 12296638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad treatment in patients with TBI
Number of subjects: 2177
Study 12296638 — intervention group
Group type: COMPARATOR
Intervention: Control group (North America)
Number of subjects: 2177
Study 9804028 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental targets and social cues (pointing, language)
Number of subjects: 0
Study 9804028 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study 7637174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (12,000 units.kg‐1) administered 15 min after starting CPB in the bubble oxygenator group
Number of subjects: 20
Study 7637174 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator group without ulinastatin
Number of subjects: 20
Study 7637174 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenator group
Number of subjects: 20
Study 2482973 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance behaviour
Number of subjects: 1168
Study 2482973 — intervention group
Group type: COMPARATOR
Intervention: Major depression
Number of subjects: 1168
Study 73313 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for 3 days every second week)
Number of subjects: 99
Study 73313 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 30565718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein oral nutrition supplement (S-ONS)
Number of subjects: 30
Study 30565718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29544579 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 200
Study 29544579 — intervention group
Group type: COMPARATOR
Intervention: Lactic acid producing probiotics
Number of subjects: 200
Study 26856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia nursing education
Number of subjects: 100
Study 26856480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no multimedia nursing education)
Number of subjects: 100
Study 24974806 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 60
Study 24974806 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES-R)
Number of subjects: 60
Study 23109023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciaglia technique
Number of subjects: 100
Study 23109023 — intervention group
Group type: COMPARATOR
Intervention: Griggs technique
Number of subjects: 100
Study 19579640 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) 12-week group
Number of subjects: 20
Study 19579640 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) 6-week group
Number of subjects: 20
Study 19579640 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study 17185047 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin dry powder inhalation (25 mg)
Number of subjects: 10
Study 17185047 — intervention group
Group type: COMPARATOR
Intervention: Nebulised colistin (158 mg)
Number of subjects: 10
Study 15584584 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (remifentanyl and propofol)
Number of subjects: 64
Study 15584584 — intervention group
Group type: COMPARATOR
Intervention: Inhaled anaesthesia (isoflurane and fentanyl)
Number of subjects: 64
Study 11466098 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (avoidance of pacifier use)
Number of subjects: 281
Study 11466098 — intervention group
Group type: COMPARATOR
Intervention: Experimental intervention
Number of subjects: 281
Study 11466098 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pacifier use (observational analysis)
Number of subjects: 281
Study 9491905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 94
Study 9491905 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 94
Study 9491905 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 94
Study 8301443 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at doses from 5 to 80 ppm
Number of subjects: 23
Study 2732981 — intervention group
Group type: COMPARATOR
Intervention: 250 mg metronidazole (two sponges per day for two days)
Number of subjects: 52
Study 2732981 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg metronidazole (one sponge per day for three days)
Number of subjects: 52
Study 30940189 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus S‐1 (intravenous infusion of irinotecan [160 mg/m2] on day 1 and oral S‐1 [80‐120 mg] on days 1‐10, repeated every 14 days)
Number of subjects: 123
Study 30940189 — intervention group
Group type: COMPARATOR
Intervention: S‐1 monotherapy (80‐120 mg/day on days 1‐14, repeated every 21 days)
Number of subjects: 123
Study 30940189 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus S‐1
Number of subjects: 123
Study 30940189 — intervention group
Group type: COMPARATOR
Intervention: S‐1 monotherapy
Number of subjects: 123
Study 28003540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding to age 6 months (EBF-6)
Number of subjects: 756
Study 28003540 — intervention group
Group type: COMPARATOR
Intervention: Non-exclusive breastfeeding (nEBF-6)
Number of subjects: 756
Study 25011019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (85,300 IU weekly for 1 year)
Number of subjects: 80
Study 25011019 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 80
Study 24682069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 µg daily
Number of subjects: 7226
Study 24682069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7226
Study 21926942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 120
Study 21926942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19956761 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g) given at 16-24 and 28-32 weeks gestation
Number of subjects: 2297
Study 19956761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297
Study 19956761 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g)
Number of subjects: 2297
Study 17725940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally 3 times, beginning the day before ERCP until the night after the procedure.
Number of subjects: 320
Study 17725940 — intervention group
Group type: COMPARATOR
Intervention: No preventive medication (Control group).
Number of subjects: 320
Study 17725940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally.
Number of subjects: 320
Study 16095435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium as empiric therapy with physician notification
Number of subjects: 449
Study 16095435 — intervention group
Group type: COMPARATOR
Intervention: Control (no physician notification or ceftriaxone sodium)
Number of subjects: 449
Study 11935149 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 89
Study 11935149 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 9895085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sameridine 0.73 mg/kg (S-Large)
Number of subjects: 12
Study 9895085 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.10 mg/kg
Number of subjects: 12
Study 9895085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sameridine 0.15 mg/kg (S-Small)
Number of subjects: 12
Study 7744150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei preparation (BLP)
Number of subjects: 138
Study 7744150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 1782929 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 W every 3 min exercise protocol
Number of subjects: 51
Study 1782929 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 W/min exercise protocol
Number of subjects: 51
Study 1782929 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossing method for VT determination
Number of subjects: 51
Study 1782929 — intervention group
Group type: EXPERIMENTAL
Intervention: VE method for VT determination
Number of subjects: 51
Study 1782929 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical methods for VT determination
Number of subjects: 51
Study 7057051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide ointment
Number of subjects: 25
Study 7057051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Crude coal tar
Number of subjects: 25
Study 7057051 — intervention group
Group type: EXPERIMENTAL
Intervention: White petrolatum
Number of subjects: 25
Study 7057051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (Fluocinonide)
Number of subjects: 25
Study 30790396 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC)
Number of subjects: 138
Study 30790396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 27456461 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative, self‐regulation intervention (blood pressure education sessions and 12 weeks of individual counseling)
Number of subjects: 118
Study 27456461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 118
Study 27456461 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (N = 118)
Number of subjects: 118
Study 25319844 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder stimulation and lumbar paravertebral massage maneuvers
Number of subjects: 127
Study 25319844 — intervention group
Group type: COMPARATOR
Intervention: Holding under the armpits (control group)
Number of subjects: 127
Study 25319844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 23916044 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine/ezogabine (600-1200 mg/d)
Number of subjects: 2
Study 23916044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2